Slide 1: Cover letter to stock exchanges: Investor Presentation
RPG LIFE SCIENCES LIMITED L Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 Email: info@rpglifesciences.com RPG LIFE SCIENCES www.rpglifesciences.com CIN : L24232MH2007PLC169354 October 19, 2023 To The Manager BSE Limi
Slide 2: Investors' Presentation H1 FY24
L R?G LIFE SCIENCES An ~» R?Ci Company Investors’ Presentation H1 FY24
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Group: One of India's fastest-growing diversified conglomerates
RPG Group: One of India's fastest-growing diversified conglomerates UNlEASHTALENT RPG Group has a business history dating back to 1820 AD in banking, textiles, jute, and tea. RPG Enterprises was founded in 1979 and currently operates in various businesses TOUCH LIVES in Infrastructure, Technology, T
Slide 5: RPG Life Sciences: An Integrated Pharmaceutical Company – APIs to Formulations
RPG Life Sciences: An Integrated Pharmaceutical Company –APIs to Formulations; R&D to Manufacturing to Marketing RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global
Slide 6: RPG Life Sciences Product Portfolio
RPG Life Sciences Product Portfolio: Strong ‘Textbook’ brands being augmented by Diligent Life Cycle Management and New Launches in Chronic and Specialty therapies Key Therapies Key Products Legacy Portfolio New Portfolio Nephrology r-----.::::.::::.::::=~-=--=--=--=--=-- ---~ Immunosuppressants Tex
Slide 7: Financial Performance
Financial Performance An <.>» R?G Company 6 L ~c:; LIFE SCIENCES
Slide 8: Journey of RPG Life Sciences
Journey of RPG Life Sciences 1 2 Process Excellence Product Portfolio, People, Business Processes Fundamentals Fixation Sales Hygiene, People, Organization 3 Sustainable Profitable Growth Revenues, Volumes, Margins 4 Benchmark 5 Performance Profitability, Leverage, Liquidity Ratios Scale-up An <.>»
Slide 9: Q2 FY24 Performance
Q2 FY24 Performance (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin - --f 34.8 39.1 27.0 ~ n a 153.6 134.8 31.0 25.5% 22.7% 23.0% 20.0% Q2 FY23 Q2 FY24 Q2 FY23 Q2 FY24 Q2 FY23 Q2 FY24 PAT & PAT Margin - -f _f EPS 25.9 15.6 20.0 12.1 16.8%
Slide 10: H1 FY24 Performance
H1 FY24 Performance (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin - --f 301.4 64.6 263.7 73.2 52.1 60.0 24.3% 21.4% 22.8% 19.8% H1 FY23 H1 FY24 H1 FY23 H1 FY24 H1 FY23 H1 FY24 PAT & PAT Margin - -f _f EPS 48.0 29.0 38.2 23.1 15.9% 14.5%
Slide 11: H1 FY24: 5 Year Trends- Key Financials
H1 FY24: 5 Year Trends- Key Financials (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations - -f __f EBITDA & EBITDA Margin _f PBT & PBT Margin 107.5 91.7 512.8 440.2 89.4 73.2 375.6 389.1 70.8 73.2 64.6 330.2 301.4 59.9 53.6 41.8 34.4 15.1 10.4% 15.9% 18.2% 20.3% 21.0% 24.3% 4.6% 1
Slide 12: 5Y Trajectory of Uninterrupted Margins Expansion continues
H1FY24: 5Y Trajectory of Uninterrupted Margins Expansion continues despite Market Challenges EBITDA:10.4% (FY19) to 24.3%(H1 FY24);PBT: 4.6% (FY19) to 21.4%(H1 FY24);PAT: 3.3% (FY19) to 15.9% (H1 FY24) EBITDA% 24.3% 20.3% PBT% 21.0% 18.2% 21.4% 16.6% 17.9% PAT% 15.9% 13.8% 15.9% 11.7% 13.2% 11.1% 11
Slide 13: H1 FY24: 5 Year Trends- Key Ratios (ROCE, ROE, D/E)
H1 FY24: 5 Year Trends- Key Ratios (ROCE, ROE, D/E) _f ROCE% _f ROE% - l Debt/Equity Ratio 22.0% 0.22 24.9% 28.5% 29.7% 18.5% 20.1% 16.4% 20.9% .111 1 .111 1 I. _ 9.7% FY19 FY20 FY21 FY22 FY23 6.7% FY19 FY20 FY21 FY22 FY23 FY19 0.06 FY20 0.01 FY21 0.00 FY22 0.00 FY23 Company continues to remain Debt
Slide 14: H1 FY24: Business Segment-wise Performance
H1 FY24: Business Segment-wise Performance Domestic Formulations contributed 66% to total sales of H1 FY24 199.0 • 16% sales growth driven by both Legacy and New products 171.8 Domestic • Growth consistently higher than the market Business Segments Formulations • New products* contribution improving
Slide 15: RPG Life Sciences ICRA Rating Reaffirmed in FY23
RPG Life Sciences ICRA Rating Reaffirmed in FY23 Long term rating reaffirmed at A Short term rating reaffirmed at A1 Outlook on long term rating has been retained as Stable The rating reaffirmation factors: ► Strong brands in the Indian Pharmaceutical Industry ► Considerable improvement in the opera
Slide 16: Business Strategy
Business Strategy An <.>» R?G Company 15 L ~c:; LIFE SCIENCES
Slide 17: Domestic Formulations (DF): Overview and Strategy
Domestic Formulations (DF): Overview and Strategy • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leading player in Immunosuppressant category • Good Cust
Slide 18: DF: Diligent implementation of 5 Pillars of Business Strategy yielding results
DF: Diligent implementation of 5 Pillars of Business Strategy yielding results 1 2 3 4 5 Product portfolio Strategic brand assets Customer coverage Sales force effectiveness Profitability rejuvenation building deepening augmentation improvement Monthly Revenue per MR (INR *New Product Contribution N
Slide 19: International Formulations (IF) Business: Overview and Strategy
International Formulations (IF) Business: Overview and Strategy • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and busine
Slide 20: APIs Business: Overview and Strategy
APIs Business: Overview and Strategy • High value, low volume, niche APIs • Footprints across geographies - LATAM, Germany, China, South • Mature stable molecules Korea, Iran, Bangladesh, Egypt, India, etc. • Provides backward integration to International • Strong customer focus – long-lasting relat
Slide 21: Infrastructure & Backend Capabilities
Infrastructure & Backend Capabilities An <.>» R?G Company 20 L ~c:; LIFE SCIENCES
Slide 22: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved Formulations Unit 2, Ankleshwar • F2 unit caters
Slide 23: Strong Backend Capabilities
Strong Backend Capabilities Quality Regulatory • All critical SOPs harmonized through CQA • Well established & evolved Regulatory function catering • Quarterly internal audit of all plants by CQA to Canada, UK, EU, Australia and emerging markets • All critical deviations, change controls and market
Slide 24: Operational Highlights
Operational Highlights An <.>» R?G Company 23 L ~c:; LIFE SCIENCES
Slide 25: Top 10 Operational Highlights
Top 10 Operational Highlights Comprehensive Life Cycle Management Strategy for DF 1 Legacy Product Naprosyn becomes the first 50 Cr+ Brand of the Company Legacy products yielding results New Product portfolio across identified segments The New Product Denosumab Sales ~5 Cr in the very first year of
Slide 26: Digitalization Initiatives: Sales and Marketing
Digitalization Initiatives: Sales and Marketing Game Changer Customer Connect Initiative Gen AI for Superior Customer Service & Impactful Marketing Anytime, Anywhere ~ Doctor Support Melanicyte transfer Initiative surgery for Stable vitiligo 0 Industry First Salesforce Excellence Initiatives Initiat
Slide 27: Digitalization Initiatives: Manufacturing and Quality Operations
Digitalization Initiatives: Manufacturing and Quality Operations Roadmap of >20 Initiatives under various stages of Implementation Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access with IRIS/ Retina • Implementation •
Slide 28: People Initiatives: Building Happy Performance focussed Culture
People Initiatives: Building Happy Performance focussed Culture I Love My Work I Feel Valued RPGLS Heroes I am Growing Outperformance recognition We Skill. You Grow. Competency building You Excel. We Applaud. continuum Motivation continuum •• Akanksha High 0 Career development Happiness Quotient I L
Slide 29: People Initiatives: Culture Glimpses
People Initiatives: Building Happy Performance focussed Culture- Glimpses Rewards & Recognition: Hi-Ftire.- Function Employee Motivation: Happy Cards illTllll !:mailers •• u.., U·••w,tluJalfuft. f-,r th,, bl .,n~ """ i rrjr ChaNir'l:af,t _J.7jaln f,.,,- PM'. 1 ,u,,cnd11~l• tlJ.' V 1w 5:.,-rc,,.! My
Slide 30: People Initiatives: Culture Glimpses
People Initiatives: Building Happy Performance focussed Culture- Glimpses Hello Happiness Forums: Monthly Townhall for Connect, Recognition and Camaraderie For Your Happ."ness @ R?G L I FE SCIENCES • hello happiness 1 RPGLS Happiness Forum 0 Monthly Town hall for Connect, Recognition hello happiness
Slide 31: People Initiatives: Culture Glimpses
People Initiatives: Building Happy Performance focussed Culture- Glimpses Parivar Tyohar Utsav Shrankhla: Virtual Celebration of Festivals with Families For Your Happiness @ • 0 hello happiness R?G L I FE SCIENCES 3 RPGLS Parivar Tyohar-Utsav Shrankhla 'II f -- ~- .. tf ~ -f- ;:1(. I II - ~ ~ , _, -
Slide 32: Awards & Recognitions
Awards & Recognitions An <.>» R?G Company 31 L ~c:; LIFE SCIENCES
Slide 33: Awarded 'Jamnalal Bajaj Award for Fair Business Practices'
RPG Life Sciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’ Jamnalal Bajaj Award for Fair Business Practices (2021-22) An <.>» R?G Company L ~c:; LIFE SCIENCES
Slide 34: RPG Life Sciences Bagged Top Awards from IDMA
RPG Life Sciences Bagged Top Awards from IDMA Industry Recognition to RPG Life Sciences Best Patent Award Best Corporate Citizen Award An <.>» R?G Company L ~c:; LIFE SCIENCES
Slide 35: Naprosyn+
New Launch Naprosyn+ bags Brand Champion of the Year Award Naprosyn+ An <.>» R?G Company L ~c:; LIFE SCIENCES
Slide 36: Committed to our Transformation Agenda
We are Committed to our Transformation Agenda to continue our upward growth trajectory Profit Growth and Focus on Revenue Growth Strong Governance Cashflows Building Domestic Formulations Business Continued diligent thrust on cost All operations within the via the identified 5 Pillars control measur
Slide 37: The Journey Ahead: 7 Pillars to Scale-up business
The Journey Ahead: Diligent work on-going on 7 Pillars to “Scale-up” business 7 Pillars Identified 1 2 3 4 5 6 7 State-of-art Targeted Lead Therapy Talent Institutionalized TECHNOLOGY Niche- focus M&As ADJACENT Development INNOVATION enablement PLANTS R&D PIPELINE Spaces /Acquisition • Focused New •
Slide 38: Thank You
••••• ••• T H A N K Y O U An <.>» R?G Company _ _ _ _ _ _ _ _ L Ri>G L1FEsc1ENcEs